Developer docs
API playgroundTry for free, no card

Search company profiles

CancerIQ

Full company profile

uuid000054e

Namestring
CancerIQ
Legal namestring
CancerIQ, Inc.
Websiteurl
canceriq.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

CancerIQ is a cloud-based precision health intelligence platform founded in 2013 and headquartered in Chicago, Illinois (Delaware-incorporated). It is purpose-built for healthcare providers — health-system oncology and genetics programs, dedicated breast centers, primary-care networks, and EHR/health-IT stakeholders — and is implemented at more than 200 clinical locations across more than 60 U.S. health systems. The platform combines evidence-based risk models (Tyrer-Cuzick, NCCN guidelines) with clinical decision support, automated pedigree and documentation generation, longitudinal care-plan management with patient/provider alerts, and analytics/revenue-tracking dashboards (including Commission on Cancer Standard 4.4 reporting). It is exposed through four role-based portals (Navigator, Specialist, Manager & Registry, Analytics) and a REST API gateway (api.canceriq.com) with Auth0-based SSO, and is bidirectionally integrated with Epic (App Orchard) and Cerner App Gallery.

CancerIQ monetizes primarily through annual, quote-based enterprise SaaS subscriptions sold via a sales-led, demo-driven motion ("Book a Demo" CTA) to enterprise buyers, with implementation and customer-success services layered on top of each contract. Two adjacent revenue streams are professional services/customer success (workflow observation, EHR integration design, program optimization) and a virtual-care service (CIQ Complete) that connects patients to a telehealth genetic-counseling network. Distribution is reinforced through the CancerIQ Lab Network — a marketplace of anchor genetic-testing labs (Invitae, Myriad, Eurofins EGL, Eurofins NTD, LabCorp) — and through EHR app-store presence. CancerIQ has raised a $14 million Series B (March 2022, co-led by Merck GHI and Amgen Ventures) plus a 2024 growth package from Decathlon Capital Partners, and has grown its screened-patient base to over 300,000.

Short descriptiontext

CancerIQ is a Chicago-based precision health intelligence platform that helps U.S. health systems scale genomics-based cancer risk assessment, hereditary screening, and high-risk care management through EHR-integrated clinical decision support, automated documentation, and a multi-lab genetic-testing marketplace.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision cancer prevention, hereditary cancer risk assessment, clinical decision support software, EHR-integrated genetic testing, oncology workflow automation
Industry2 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code2 codes
  • Software Publishers51321
  • Computer Systems Design and Related Services5415
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Precision Health / Hereditary Cancer Risk Software
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise SaaS Subscription (Software & Services)
TypeSubscription Recurring
Description

Recurring SaaS subscription contracts sold to enterprise healthcare buyers (health systems, breast centers, oncology and genetics programs, primary care). Pricing is quote-based and not publicly disclosed. Bundles core platform modules (Screening, Risk Assessment, Patient Navigation, Care Plan Management, Analytics & Revenue Tracking) plus professional services for workflow planning, EHR integration, and customer success support. Customers are referenced at 200+ clinical locations.

canceriq.com
2Professional Services / Customer Success
TypeProfessional Services
Description

Implementation and customer success services including initial workflow observation, customized implementation planning, EHR integration design, and ongoing program optimization, often delivered alongside the SaaS subscription to drive adoption and ROI.

canceriq.com
3Virtual Care / Genetic Counseling Services
TypeManaged Services
Description

Virtual care offering (CIQ Complete Call) that connects patients to genetic counseling and telehealth services, generating downstream clinical services revenue tied to genetic risk assessment and counseling encounters.

blog.canceriq.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise SaaS — quote-based
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing not publicly disclosed. Sales-led enterprise motion with a "Book a Demo" CTA; contract terms not stated.

canceriq.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

CancerIQ is a cloud-based precision health intelligence platform that health systems use to identify patients at hereditary cancer risk, run genetic risk assessments at the point of care, and navigate high-risk patients into appropriate genetic testing, screening and preventive care. The platform combines risk-stratification algorithms, automated pedigree and documentation generation, a multi-lab test ordering marketplace, EHR-native workflows, longitudinal care management and analytics. It is sold primarily as an enterprise SaaS subscription with professional services, and is deployed across 200+ clinical locations in the United States.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CancerIQ is a platform-plus-modules architecture rather than a single monolithic product. The CancerIQ Platform serves as the core precision health intelligence solution, layered with four primary workflow modules — Navigator (patient screening), Specialist (genetic-counselor workspace), Manager (longitudinal patient management & registry), and Analytics (reporting, including CoC Standard 4.4 dashboards) — and is complemented by the services Customer Success and CIQ Complete (telehealth genetic counseling). On top of this core, CancerIQ offers use-case solutions: REACH (For Oncology), For Genetics, For Breast Programs (breast centers), and For EHRs (EHR integration). The platform is further extended by the CancerIQ Lab Network, a marketplace of trusted genetic testing labs (Invitae, Myriad Genetics, Eurofins EGL, Eurofins NTD, LabCorp) embedded directly in the ordering workflow. Modules and solutions are designed to be used together or with the EHR integration.

Product and service3 records
1CancerIQ Platform
CategoryCore SaaS Platform
Description

Integrated precision health intelligence SaaS platform that helps health systems scale access to genomics and innovations in oncology, covering screening, risk assessment, patient navigation, care plan management, and analytics & revenue tracking. Powered by what CancerIQ describes as healthcare's largest precision prevention dataset; deployed across 200+ clinical locations.

2CIQ Complete (Virtual Care)
CategoryService - Telehealth Genetic Counseling
Description

Virtual care service that connects patients to CancerIQ's telehealth genetic counseling network, providing expert genetic guidance remotely as a downstream services offering tied to genetic risk assessment encounters.

3CancerIQ Lab Network
CategoryAdd-on - Lab Marketplace
Description

Marketplace module of trusted genetic testing labs (Invitae, Myriad Genetics, Eurofins EGL, Eurofins NTD, LabCorp) embedded in the CancerIQ platform that prepopulates test requisitions and insurance prior-authorization forms and enables ordering from any vendor at the point of care.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierFlagship Diagnostic PartnerTypeStrategic or Co-development PartnerAnnounced on2026-01-27
Description

Strategic partnership integrating Rhythm's geneType Cancer Risk Assessment (polygenic risk scores combined with clinical/family history data across six cancer types, providing 5-year and lifetime risk estimates) into CancerIQ's workflow across 60+ health systems. Expands CancerIQ's diagnostic offerings while giving Rhythm broader commercial reach through U.S. healthcare providers.

Strategic tierFlagship Clinical Partner For Lung Cancer ScreeningTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

Partnership combining CancerIQ's risk-based patient identification and engagement with Azra AI's AI-powered imaging follow-up for low-dose CT lung cancer screening. Real-world Nebraska Medicine deployment showed a 270% monthly increase in scheduled LDCT scans and successful Stage 1A lung cancer diagnoses; Azra AI reports 98% precision, 7-day reduction in time to treatment, and 20% annual net patient revenue growth for partners.

Strategic tierFlagship Research PartnerTypeStrategic or Co-development PartnerAnnounced on2025-02-25
Description

Co-published a study in Genetics in Medicine (Feb 25, 2025) showing outstanding data integrity when transitioning from Progeny to CancerIQ. Research/clinical collaboration validating the platform's data quality.

Strategic tierIndustry Consortium MembershipTypeStrategic or Co-development PartnerAnnounced on2023-09-10
Description

CancerIQ joined the CancerX Moonshot initiative, an innovative partnership led by the Digital Medicine Society to accelerate innovation in cancer care.

Strategic tierAnchor Member Of Canceriq Lab NetworkTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-11-19
Description

Anchor member of the CancerIQ Lab Network (launched November 2020). Invitae is listed within CancerIQ's platform at the point of care, and CancerIQ prepopulates test requisitions and insurance prior-authorization forms with data from the encounter.

Strategic tierAnchor Member Of Canceriq Lab NetworkTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-11-19
Description

Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering at the point of care.

Strategic tierAnchor Member Of Canceriq Lab NetworkTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-11-19
Description

Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.

Strategic tierAnchor Member Of Canceriq Lab NetworkTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-11-19
Description

Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.

Strategic tierAnchor Member Of Canceriq Lab NetworkTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-11-19
Description

Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.

Strategic tierFlagship Telehealth PartnerTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Combined telehealth genetic counseling solutions with CancerIQ's cancer risk assessment platform to bring genetic expertise directly to patients regardless of location.

Strategic tierFlagship Ehr Integration PartnerTypeTechnology or Integration
Description

CancerIQ is integrated with Epic's App Orchard and works as a smart application within the Epic workflow — OSF HealthCare uses CancerIQ "all within Epic's workflow," and Adventist Health has integrated CancerIQ with Cerner.

12Cerner (Oracle Health) — Cerner App Gallery
Strategic tierFlagship Ehr Integration PartnerTypeTechnology or Integration
Description

Adventist Health integrated CancerIQ with Cerner in 2019; CancerIQ is listed in the Cerner App Gallery for embedded deployment.

blog.canceriq.com
Strategic tierFounding Research PartnerTypeStrategic or Co-development Partner
Description

Early academic partner since CancerIQ's founding in 2014; co-developed genetics workflow solutions with Dr. Olufunmilayo (Funmi) Olopade, who is also CancerIQ's co-founder and Chief Scientific Officer.

Strategic tierEarly Strategic PartnerTypeStrategic or Co-development Partner
Description

Early partner since CancerIQ's founding era; co-developed the original genetic counseling and testing workflow for high-risk patient populations; hosts the annual Clinical Cancer Genetics & Genomics Conference at which CancerIQ presents.

15McKesson (referenced)
Strategic tierMinor Industry ReferenceTypeGTM or Marketing Partner
Description

McKesson published a release referencing CancerIQ's $14 million Series B funding round, indicating industry-aligned distribution/PR overlap.

builtinchicago.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Syapse is a precision medicine platform for oncology that helps health systems use real-world evidence and molecular data to inform cancer treatment decisions. Directly comparable to CancerIQ as enterprise health-system software turning molecular/clinical data into actionable oncology pathways.

TypeDirect peer
Description

2bPrecise is a precision medicine decision-support platform that integrates genomic and clinical data into the EHR workflow for oncologists and genetics providers. Direct competitor to CancerIQ, sharing the same EHR-embedded precision-oncology CDS model and target buyer (oncology and genetics programs).

TypeBroad incumbent
Description

Flatiron Health (Roche subsidiary) is a leading oncology-specific EHR, real-world data, and clinical trials platform. Comparable to CancerIQ as a deeply embedded oncology data and decision support company, but at much larger scale and broader scope across community oncology and life sciences R&D.

4Tempus
TypeBroad incumbent
Description

Tempus combines molecular profiling, real-world data, and AI-driven clinical decision support in oncology. Comparable to CancerIQ in providing AI-enabled oncology intelligence to clinicians, but Tempus also operates its own diagnostic lab, giving it a vertically integrated model rather than a software-only platform.

5N-of-One (Qiagen Clinical Insights)
TypeDirect peer
Description

N-of-One, now part of Qiagen Clinical Insights, provides molecular tumor board interpretation and clinical decision support for oncologists. Direct comparable to CancerIQ's molecular interpretation and clinical pathway generation capabilities, serving similar oncology and pathology customers.

6Perthera
TypeEmerging player
Description

Perthera is a precision oncology decision-support company that combines multi-omic profiling with AI-driven treatment recommendations and molecular tumor board services. Emerging player with overlap in cancer risk assessment and clinical pathway tools for community oncology.

TypeRegional player
Description

Navican is the precision cancer care subsidiary of Intermountain Healthcare, offering precision oncology decision support and tumor board services. Comparable to CancerIQ as an oncology precision-medicine platform, but primarily serves Intermountain-affiliated and regional US health systems rather than the nationwide footprint CancerIQ has built.

TypeBroad incumbent
Description

Foundation Medicine (Roche subsidiary) provides comprehensive genomic profiling and a molecular insights platform used by oncologists. Comparable to CancerIQ on the molecular interpretation side, but Foundation is a diagnostic lab first with a software layer, while CancerIQ is software-first with a lab network partner ecosystem.

TypeBroad incumbent
Description

Philips offers oncology informatics solutions including clinical decision support, tumor board workflows, and population health analytics within its broader health technology portfolio. Broad incumbent with overlapping CDS and oncology pathway capabilities, though not focused specifically on hereditary cancer and genetic risk assessment.

TypeBroad incumbent
Description

Caris is a molecular profiling and precision oncology company that combines comprehensive tumor profiling with an AI-driven molecular profiling platform (MI Profile, MI Cancer Seek) and an oncology decision support network. Comparable to CancerIQ at the intersection of cancer genomics and clinical intelligence, but vertically integrated with its own lab.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CancerIQ

Precision Health / Hereditary Cancer Risk Softwarecanceriq.com

CancerIQ is a Chicago-based precision health intelligence platform that helps U.S. health systems scale genomics-based cancer risk assessment, hereditary screening, and high-risk care management through EHR-integrated clinical decision support, automated documentation, and a multi-lab genetic-testing marketplace.

What CancerIQ does

CancerIQ is a cloud-based precision health intelligence platform founded in 2013 and headquartered in Chicago, Illinois (Delaware-incorporated). It is purpose-built for healthcare providers — health-system oncology and genetics programs, dedicated breast centers, primary-care networks, and EHR/health-IT stakeholders — and is implemented at more than 200 clinical locations across more than 60 U.S. health systems. The platform combines evidence-based risk models (Tyrer-Cuzick, NCCN guidelines) with clinical decision support, automated pedigree and documentation generation, longitudinal care-plan management with patient/provider alerts, and analytics/revenue-tracking dashboards (including Commission on Cancer Standard 4.4 reporting). It is exposed through four role-based portals (Navigator, Specialist, Manager & Registry, Analytics) and a REST API gateway (api.canceriq.com) with Auth0-based SSO, and is bidirectionally integrated with Epic (App Orchard) and Cerner App Gallery.

CancerIQ monetizes primarily through annual, quote-based enterprise SaaS subscriptions sold via a sales-led, demo-driven motion ("Book a Demo" CTA) to enterprise buyers, with implementation and customer-success services layered on top of each contract. Two adjacent revenue streams are professional services/customer success (workflow observation, EHR integration design, program optimization) and a virtual-care service (CIQ Complete) that connects patients to a telehealth genetic-counseling network. Distribution is reinforced through the CancerIQ Lab Network — a marketplace of anchor genetic-testing labs (Invitae, Myriad, Eurofins EGL, Eurofins NTD, LabCorp) — and through EHR app-store presence. CancerIQ has raised a $14 million Series B (March 2022, co-led by Merck GHI and Amgen Ventures) plus a 2024 growth package from Decathlon Capital Partners, and has grown its screened-patient base to over 300,000.

CancerIQ firmographics

Firmographics
Name
CancerIQ
Legal name
CancerIQ, Inc.
Website
https://canceriq.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
CancerIQ is a Chicago-based precision health intelligence platform that helps U.S. health systems scale genomics-based cancer risk assessment, hereditary screening, and high-risk care management through EHR-integrated clinical decision support, automated documentation, and a multi-lab genetic-testing marketplace.
Ownership category
akta.pro rank

CancerIQ industry classification

Industry
Product category
Precision Health / Hereditary Cancer Risk Software
NAICS
Software Publishers (51321), Computer Systems Design and Related Services (5415)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Precision cancer prevention
  • Hereditary cancer risk assessment
  • Clinical decision support software
  • EHR-integrated genetic testing
  • Oncology workflow automation

Where CancerIQ is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices2 records

Markets served

CancerIQ business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise SaaS Subscription (Software & Services): Recurring SaaS subscription contracts sold to enterprise healthcare buyers (health systems, breast centers, oncology and genetics programs, primary care). Pricing is quote-based and not publicly disclosed. Bundles core platform modules (Screening, Risk Assessment, Patient Navigation, Care Plan Management, Analytics & Revenue Tracking) plus professional services for workflow planning, EHR integration, and customer success support. Customers are referenced at 200+ clinical locations.
  2. Professional Services / Customer Success: Implementation and customer success services including initial workflow observation, customized implementation planning, EHR integration design, and ongoing program optimization, often delivered alongside the SaaS subscription to drive adoption and ROI.
  3. Virtual Care / Genetic Counseling Services: Virtual care offering (CIQ Complete Call) that connects patients to genetic counseling and telehealth services, generating downstream clinical services revenue tied to genetic risk assessment and counseling encounters.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise SaaS — quote-based

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

CancerIQ product offering

Product offering

Core offering

CancerIQ is a cloud-based precision health intelligence platform that health systems use to identify patients at hereditary cancer risk, run genetic risk assessments at the point of care, and navigate high-risk patients into appropriate genetic testing, screening and preventive care. The platform combines risk-stratification algorithms, automated pedigree and documentation generation, a multi-lab test ordering marketplace, EHR-native workflows, longitudinal care management and analytics. It is sold primarily as an enterprise SaaS subscription with professional services, and is deployed across 200+ clinical locations in the United States.

Product overview

CancerIQ is a platform-plus-modules architecture rather than a single monolithic product. The CancerIQ Platform serves as the core precision health intelligence solution, layered with four primary workflow modules — Navigator (patient screening), Specialist (genetic-counselor workspace), Manager (longitudinal patient management & registry), and Analytics (reporting, including CoC Standard 4.4 dashboards) — and is complemented by the services Customer Success and CIQ Complete (telehealth genetic counseling). On top of this core, CancerIQ offers use-case solutions: REACH (For Oncology), For Genetics, For Breast Programs (breast centers), and For EHRs (EHR integration). The platform is further extended by the CancerIQ Lab Network, a marketplace of trusted genetic testing labs (Invitae, Myriad Genetics, Eurofins EGL, Eurofins NTD, LabCorp) embedded directly in the ordering workflow. Modules and solutions are designed to be used together or with the EHR integration.

Differentiator

Problem solved

Functional benefit

Products and services

  • CancerIQ Platform Integrated precision health intelligence SaaS platform that helps health systems scale access to genomics and innovations in oncology, covering screening, risk assessment, patient navigation, care plan management, and analytics & revenue tracking. Powered by what CancerIQ describes as healthcare's largest precision prevention dataset; deployed across 200+ clinical locations.
  • CIQ Complete (Virtual Care) Virtual care service that connects patients to CancerIQ's telehealth genetic counseling network, providing expert genetic guidance remotely as a downstream services offering tied to genetic risk assessment encounters.
  • CancerIQ Lab Network Marketplace module of trusted genetic testing labs (Invitae, Myriad Genetics, Eurofins EGL, Eurofins NTD, LabCorp) embedded in the CancerIQ platform that prepopulates test requisitions and insurance prior-authorization forms and enables ordering from any vendor at the point of care.

Companies that use CancerIQ

Customer profile

Named customers16 records

Segments4 records

Ideal customer profiles4 records

CancerIQ technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability7 records

Feature9 records

CancerIQ partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered flagship diagnostic partner, flagship clinical partner for lung cancer screening, flagship research partner, industry consortium membership, anchor member of canceriq lab network, flagship telehealth partner, flagship ehr integration partner, founding research partner, early strategic partner and minor industry reference.

  • Rhythm Biosciencesflagship diagnostic partnerStrategic or Co-development Partner · 27 January 2026Strategic partnership integrating Rhythm's geneType Cancer Risk Assessment (polygenic risk scores combined with clinical/family history data across six cancer types, providing 5-year and lifetime risk estimates) into CancerIQ's workflow across 60+ health systems. Expands CancerIQ's diagnostic offerings while giving Rhythm broader commercial reach through U.S. healthcare providers.
  • Azra AIflagship clinical partner for lung cancer screeningStrategic or Co-development Partner · 26 January 2026Partnership combining CancerIQ's risk-based patient identification and engagement with Azra AI's AI-powered imaging follow-up for low-dose CT lung cancer screening. Real-world Nebraska Medicine deployment showed a 270% monthly increase in scheduled LDCT scans and successful Stage 1A lung cancer diagnoses; Azra AI reports 98% precision, 7-day reduction in time to treatment, and 20% annual net patient revenue growth for partners.
  • Fred Hutchinson Cancer Centerflagship research partnerStrategic or Co-development Partner · 25 February 2025Co-published a study in Genetics in Medicine (Feb 25, 2025) showing outstanding data integrity when transitioning from Progeny to CancerIQ. Research/clinical collaboration validating the platform's data quality.
  • CancerX Moonshot Initiative (Digital Medicine Society)industry consortium membershipStrategic or Co-development Partner · 10 September 2023CancerIQ joined the CancerX Moonshot initiative, an innovative partnership led by the Digital Medicine Society to accelerate innovation in cancer care.
  • Invitaeanchor member of canceriq lab networkChannel Partner/ Reseller/ Distributor · 19 November 2020Anchor member of the CancerIQ Lab Network (launched November 2020). Invitae is listed within CancerIQ's platform at the point of care, and CancerIQ prepopulates test requisitions and insurance prior-authorization forms with data from the encounter.
  • Myriad Geneticsanchor member of canceriq lab networkChannel Partner/ Reseller/ Distributor · 19 November 2020Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering at the point of care.
  • Eurofins EGL Genetic Diagnosticsanchor member of canceriq lab networkChannel Partner/ Reseller/ Distributor · 19 November 2020Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.
  • Eurofins NTDanchor member of canceriq lab networkChannel Partner/ Reseller/ Distributor · 19 November 2020Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.
  • LabCorpanchor member of canceriq lab networkChannel Partner/ Reseller/ Distributor · 19 November 2020Anchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.
  • GeneMattersflagship telehealth partnerStrategic or Co-development Partner · 1 January 2019Combined telehealth genetic counseling solutions with CancerIQ's cancer risk assessment platform to bring genetic expertise directly to patients regardless of location.
  • Epic Systems (Epic App Orchard)flagship ehr integration partnerTechnology or IntegrationCancerIQ is integrated with Epic's App Orchard and works as a smart application within the Epic workflow — OSF HealthCare uses CancerIQ "all within Epic's workflow," and Adventist Health has integrated CancerIQ with Cerner.
  • Cerner (Oracle Health) — Cerner App Galleryflagship ehr integration partnerTechnology or IntegrationAdventist Health integrated CancerIQ with Cerner in 2019; CancerIQ is listed in the Cerner App Gallery for embedded deployment.
  • University of Chicago (Dr. Olopade, Dr. Guindalini, Dr. Obeid)founding research partnerStrategic or Co-development PartnerEarly academic partner since CancerIQ's founding in 2014; co-developed genetics workflow solutions with Dr. Olufunmilayo (Funmi) Olopade, who is also CancerIQ's co-founder and Chief Scientific Officer.
  • City of Hope (Kathy Blazer, Dr. Weitzel)early strategic partnerStrategic or Co-development PartnerEarly partner since CancerIQ's founding era; co-developed the original genetic counseling and testing workflow for high-risk patient populations; hosts the annual Clinical Cancer Genetics & Genomics Conference at which CancerIQ presents.
  • McKesson (referenced)minor industry referenceGTM or Marketing PartnerMcKesson published a release referencing CancerIQ's $14 million Series B funding round, indicating industry-aligned distribution/PR overlap.

Scale indicators20 records

Recent moves6 records

Expansion highlights6 records

CancerIQ competitors and assessment

Company assessment

Direct peers

  • Syapse: Syapse is a precision medicine platform for oncology that helps health systems use real-world evidence and molecular data to inform cancer treatment decisions. Directly comparable to CancerIQ as enterprise health-system software turning molecular/clinical data into actionable oncology pathways.
  • 2bPrecise: 2bPrecise is a precision medicine decision-support platform that integrates genomic and clinical data into the EHR workflow for oncologists and genetics providers. Direct competitor to CancerIQ, sharing the same EHR-embedded precision-oncology CDS model and target buyer (oncology and genetics programs).
  • N-of-One (Qiagen Clinical Insights): N-of-One, now part of Qiagen Clinical Insights, provides molecular tumor board interpretation and clinical decision support for oncologists. Direct comparable to CancerIQ's molecular interpretation and clinical pathway generation capabilities, serving similar oncology and pathology customers.

Broad incumbents

  • Flatiron Health: Flatiron Health (Roche subsidiary) is a leading oncology-specific EHR, real-world data, and clinical trials platform. Comparable to CancerIQ as a deeply embedded oncology data and decision support company, but at much larger scale and broader scope across community oncology and life sciences R&D.
  • Tempus: Tempus combines molecular profiling, real-world data, and AI-driven clinical decision support in oncology. Comparable to CancerIQ in providing AI-enabled oncology intelligence to clinicians, but Tempus also operates its own diagnostic lab, giving it a vertically integrated model rather than a software-only platform.
  • Foundation Medicine: Foundation Medicine (Roche subsidiary) provides comprehensive genomic profiling and a molecular insights platform used by oncologists. Comparable to CancerIQ on the molecular interpretation side, but Foundation is a diagnostic lab first with a software layer, while CancerIQ is software-first with a lab network partner ecosystem.
  • Philips Oncology Informatics: Philips offers oncology informatics solutions including clinical decision support, tumor board workflows, and population health analytics within its broader health technology portfolio. Broad incumbent with overlapping CDS and oncology pathway capabilities, though not focused specifically on hereditary cancer and genetic risk assessment.
  • Caris Life Sciences: Caris is a molecular profiling and precision oncology company that combines comprehensive tumor profiling with an AI-driven molecular profiling platform (MI Profile, MI Cancer Seek) and an oncology decision support network. Comparable to CancerIQ at the intersection of cancer genomics and clinical intelligence, but vertically integrated with its own lab.

Emerging players

  • Perthera: Perthera is a precision oncology decision-support company that combines multi-omic profiling with AI-driven treatment recommendations and molecular tumor board services. Emerging player with overlap in cancer risk assessment and clinical pathway tools for community oncology.

Regional players

  • Navican (Intermountain Healthcare): Navican is the precision cancer care subsidiary of Intermountain Healthcare, offering precision oncology decision support and tumor board services. Comparable to CancerIQ as an oncology precision-medicine platform, but primarily serves Intermountain-affiliated and regional US health systems rather than the nationwide footprint CancerIQ has built.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CancerIQ social profiles

Digital presence

CancerIQ compliance and trust

Trust signal

Compliance3 records

CancerIQ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CancerIQ leadership team

Management profile

Number of profiles

Profiles8 records

CancerIQ funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CancerIQ M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CancerIQ

What does CancerIQ do?

CancerIQ is a cloud-based precision health intelligence platform that health systems use to identify patients at hereditary cancer risk, run genetic risk assessments at the point of care, and navigate high-risk patients into appropriate genetic testing, screening and preventive care. The platform combines risk-stratification algorithms, automated pedigree and documentation generation, a multi-lab test ordering marketplace, EHR-native workflows, longitudinal care management and analytics. It is sold primarily as an enterprise SaaS subscription with professional services, and is deployed across 200+ clinical locations in the United States.

Is CancerIQ a public or private company?

CancerIQ is a private company. It is classified as venture growth investor backed and is currently operating.

When was CancerIQ founded?

CancerIQ was founded in 2013. It employs 11 to 50 people.

Where is CancerIQ based?

CancerIQ is headquartered in Chicago, United States, in the North America region.

How does CancerIQ make money?

Three revenue lines are on record. Enterprise SaaS Subscription (Software & Services) is the primary driver. The others are professional Services / Customer Success and virtual Care / Genetic Counseling Services.

Who are CancerIQ's main competitors?

Direct peers on record are Syapse, 2bPrecise and N-of-One (Qiagen Clinical Insights). Broad incumbents are Flatiron Health, Tempus, Foundation Medicine, Philips Oncology Informatics and Caris Life Sciences. Perthera is listed as an emerging player. Navican (Intermountain Healthcare) is listed as a regional player.

Does CancerIQ have an API?

Yes. CancerIQ exposes an API at api.canceriq.com that is accessed via the OAuth2 protocol (brokered through Auth0) during user authentication. No public documentation, SDKs, sample code, rate limits, or feature description were provided in the source material.

What industry is CancerIQ in?

CancerIQ's product category is Precision Health / Hereditary Cancer Risk Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLALAGAH, Oncology Telemedicine Platforms. Its NAICS code is 51321 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HIT ConsultantCancerIQ Expands Native Epic Integrations to Automate Cancer Screening and Survivorship Across 275 ClinicsCancerIQ expanded its native Epic integrations to 275 clinics across 60+ health systems, deploying a chart-aware provider tool and Risk Hub. The FHIR R4-based integration auto-ingests patient data and embeds clinical guidelines for genetic testing and screening. The rollout reaches roughly one in 10 patients nationwide.PR NewswireCancerIQ Deepens EHR Integrations to Identify and Guide More Patients Through Cancer Screening, Testing and SurveillanceCancerIQ announced updated Epic integrations to support cancer screening, testing, and surveillance within EHR workflows. The updates expand chart-aware risk assessment and provider applications, and are available to all customers.PR NewswireEon, CancerIQ Partner to Find At-Risk Patients Earlier and Drive Completion of Recommended CareEon and CancerIQ announced a partnership to give health systems access to both upstream risk identification and downstream incidental findings management. CancerIQ has driven a 4.2x increase in supplemental screening and an 8.9x average ROI, while Eon has achieved over 90% follow-up completion rates and up to a 12.5x increase in downstream diagnostic exams.AJMCFeyi Olopade Ayodele on Informing Patients of the Benefits of Genetic Screening for CancerCancerIQ is implementing strategies to inform patients about the benefits of genetic screening for early cancer detection. Their approach involves collaborating with healthcare providers to develop clear communication methods that simplify complex information for patients. Despite these efforts, challenges remain, particularly regarding the time required for providers to incorporate genetic evaluations into patient visits and the logistical barriers that may hinder access to these services.OSF HealthCareCancerIQ helps school administrator find her cancer earlyCancerIQ, a Chicago-based startup, partnered with OSF HealthCare to deploy its hereditary cancer risk assessment tool across more than 75,600 patients since 2015. The initiative resulted in over 3,100 changes to patient care plans, such as enhanced screening schedules and genetic testing, which led to the early detection of stage 1a breast cancer for one school administrator. OSF HealthCare aims to expand the use of this FDA-cleared tool throughout its hospitals and clinics to improve prevention and treatment outcomes.AijournCancerIQ Expands Diagnostic Network with Addition of geneType™ PRS Test from Rhythm BiosciencesCancerIQ has integrated the geneType™ cancer risk assessment test from Rhythm Biosciences into its platform, expanding diagnostic options across its network of over 60 health systems. The test enhances risk prediction by incorporating polygenic risk scores and clinical data for six cancer types.PR NewswireCancerIQ Expands Diagnostic Network with Addition of geneType™ PRS Test from Rhythm BiosciencesCancerIQ announced that Rhythm Biosciences' geneType™ Cancer Risk Assessment test is now available on its precision health platform, expanding diagnostic tools across its network of 60+ health systems in the US. The geneType™ test combines polygenic risk scores with clinical and family history to provide 5-year and lifetime cancer risk estimates across six cancer types. The partnership integrates the test into existing clinical workflows, enabling providers to order the assessment directly through CancerIQ's EHR-integrated platform.YnaijaTop 10 HealthTech Founders Transforming Healthcare in NigeriaA new generation of health tech founders in Nigeria is significantly transforming the healthcare sector by utilizing technology to address various challenges. Key figures include Folake Owodunni of Emergency Response Africa, who has improved ambulance services, and Feyi Olopade of CancerIQ, known for enhancing cancer risk identification during the COVID-19 pandemic. These entrepreneurs are making quality healthcare more accessible to Nigerians, positioning themselves as pivotal players in the health tech industry.Hackensack Meridian HealthCancer Risk Assessment & Early DetectionHackensack Meridian Health’s John Theurer Cancer Center has launched the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine, offering a cancer risk assessment and early detection program in New Jersey. This program is designed to identify cancer risk in individuals, promote early diagnosis, and potentially increase survival rates, with a tool provided by CancerIQ. The initiative represents a significant step in scaling cancer screening and interception efforts in the state.Daily TelegraphRhythm Biosciences partners with CancerIQRhythm Biosciences has announced a strategic partnership with US digital healthcare platform CancerIQ to integrate its geneType cancer risk assessment into CancerIQ's workflow, enabling healthcare providers to order tests more efficiently. The partnership aims to expand test volumes, accelerate revenue growth, and strengthen Rhythm's presence in the US market by embedding its technology in a platform already used by over 65 US health systems. The collaboration supports broader adoption of genomic risk assessment tools and scalable deployment across large healthcare networks in the United States.